NF-κB in aging and disease

Aging and Disease

Volumn 2, Issue 6, 2011, Pages 449-465

  Tilstra, Jeremy S ^a   Clauson, Cheryl L ^a   Niedernhofer, Laura J ^a,b   Robbins, Paul D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Aging; Inflammation; NF B; Senescence

Indexed keywords

MAMMALIA;

EID: 84863544685     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Rattan SI (2006). Theories of biological aging: genes, proteins, and free radicals. Free Radic Res, 40:1230-8.
2. Kirkwood TB (2005). Understanding the odd science of aging. Cell, 120:437-47.
3. Adler A, Sinha, S., Kawahara, TLA., Zhang, JY., Segal, E., Chang, HY. (2007). Motif module map reveals enforcement of aging by continual NF-kB activity. Genes Dev, 21.
4. Sen R and Baltimore D (1986). Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 46:705-16.
5. Sen R and Baltimore D (1986). Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell, 47:921-8.
6. Verma IM (2004). Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann Rheum Dis, 63 Suppl 2:ii57-ii61.
7. Gilmore T (2009). Rel/NF-kB Transcription Factors. www.nf-kb.org.
8. Hayden MS and Ghosh S (2008). Shared principles in NF-kappaB signaling. Cell, 132:344-62.
9. Adib-Conquy M, Adrie C, Moine P, Asehnoune K, Fitting C, Pinsky MR, Dhainaut JF, and Cavaillon JM (2000). NF-kappaB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am J Respir Crit Care Med, 162:1877-83.
10. Chow JC, Young DW, Golenbock DT, Christ WJ, and Gusovsky F (1999). Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem, 274:10689-92.
11. Xu H, An H, Yu Y, Zhang M, Qi R, and Cao X (2003). Ras participates in CpG oligodeoxynucleotide signaling through association with toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor 6 complex formation in macrophages. J Biol Chem, 278:36334-40.
12. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, and Aderem A (2001). The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature, 410:1099-103.
13. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, and Nunez G (2001). Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem, 276:4812-8.
14. Huang TT, Wuerzberger-Davis SM, Wu ZH, and Miyamoto S (2003). Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell, 115:565-76.
15. Wu ZH, Shi Y, Tibbetts RS, and Miyamoto S (2006). Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science, 311:1141-6.
16. Bubici C, Papa S, Dean K, and Franzoso G (2006). Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene, 25:6731-48.
17. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, and Ghosh S (2000). Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science, 289:1550-4.
18. Tak PP and Firestein GS (2001). NF-kappaB: a key role in inflammatory diseases. J Clin Invest, 107:7-11.
19. Gilmore TD (2006). Introduction to NF-kappaB: players, pathways, perspectives. Oncogene, 25:6680-4.
20. Sil AK, Maeda S, Sano Y, Roop DR, and Karin M (2004). IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature, 428:660-4.
21. Hiscott J, Nguyen TL, Arguello M, Nakhaei P, and Paz S (2006). Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene, 25:6844-67.
22. Hayden MS and Ghosh S (2004). Signaling to NF-kappaB. Genes Dev, 18:2195-224.
23. Solt LA, Madge LA, Orange JS, and May MJ (2007). Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta. J Biol Chem, 282:8724-33.
24. Carmody RJ, Ruan Q, Palmer S, Hilliard B, and Chen YH (2007). Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade. Science, 317:675-8.
25. Lim W, Cho J, Kwon HY, Park Y, Rhyu MR, and Lee Y (2009). Hypoxia-inducible factor 1 alpha activates and is inhibited by unoccupied estrogen receptor beta. FEBS Lett, 583:1314-8.
26. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, and Ben-Ze'ev A (1999). The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A, 96:5522-7.
27. Li Y, Wang Z, Kong D, Murthy S, Dou QP, Sheng S, Reddy GP, and Sarkar FH (2007). Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem, 282:21542-50.
28. Scheidereit C (2006). IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene, 25:6685-705.
29. Niedernhofer LJ and Robbins PD (2008). Signaling mechanisms involved in the response to genotoxic stress and regulating lifespan. Int J Biochem Cell Biol, 40:176-80.
30. Adler A, Sinha, S., Kawahara, TLA., Zhang, JY., Segal, E., Chang, HY. (2007). Motif module map reveals enforcement of aging by continual NF-kB activity. Genes Dev, 21.
31. Bernard D, Quatannens B, Begue A, Vandenbunder B, and Abbadie C (2001). Antiproliferative and antiapoptotic effects of crel may occur within the same cells via the up-regulation of manganese superoxide dismutase. Cancer Res, 61:2656-64.
32. Bernard D, Gosselin K, Monte D, Vercamer C, Bouali F, Pourtier A, Vandenbunder B, and Abbadie C (2004). Involvement of Rel/nuclear factor-kappaB transcription factors in keratinocyte senescence. Cancer Res, 64:472-81.
33. Seitz CS, Deng H, Hinata K, Lin Q, and Khavari PA (2000). Nuclear factor kappaB subunits induce epithelial cell growth arrest. Cancer Res, 60:4085-92.
34. Wang J, Jacob NK, Ladner KJ, Beg A, Perko JD, Tanner SM, Liyanarachchi S, Fishel R, and Guttridge DC (2009). RelA/p65 functions to maintain cellular senescence by regulating genomic stability and DNA repair. EMBO Rep, 10:1272-8.
35. Kriete A, Mayo KL, Yalamanchili N, Beggs W, Bender P, Kari C, and Rodeck U (2008). Cell autonomous expression of inflammatory genes in biologically aged fibroblasts associated with elevated NF-kappaB activity. Immun Ageing, 5:5.
36. Helenius M, Hanninen M, Lehtinen SK, and Salminen A (1996). Changes associated with aging and replicative senescence in the regulation of transcription factor nuclear factor-kappa B. Biochem J, 318 (Pt 2):603-8.
37. Korhonen P, Helenius M, and Salminen A (1997). Age-related changes in the regulation of transcription factor NF-kappa B in rat brain. Neurosci Lett, 225:61-4.
38. Bregegere F, Milner Y, and Friguet B (2006). The ubiquitin-proteasome system at the crossroads of stress-response and ageing pathways: a handle for skin care? Ageing Res Rev, 5:60-90.
39. Giardina C and Hubbard AK (2002). Growing old with nuclear factor-kappaB. Cell Stress Chaperones, 7:207-12.
40. Xiao ZQ and Majumdar AP (2000). Induction of transcriptional activity of AP-1 and NF-kappaB in the gastric mucosa during aging. Am J Physiol Gastrointest Liver Physiol, 278:G855-65.
41. Helenius M, Hanninen M, Lehtinen SK, and Salminen A (1996). Aging-induced up-regulation of nuclear binding activities of oxidative stress responsive NF-kB transcription factor in mouse cardiac muscle. J Mol Cell Cardiol, 28:487-98.
42. Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, Lin M, McCord RA, Ongaigui KC, Boxer LD, Chang HY, and Chua KF (2009). SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell, 136:62-74.
43. Natoli G (2009). When sirtuins and NF-kappaB collide. Cell, 136:19-21.
44. Coppe JP, Patil CK, Rodier F, Krtolica A, Beausejour CM, Parrinello S, Hodgson JG, Chin K, Desprez PY, and Campisi J (2010). A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS One, 5:e9188.
45. Campisi J (2001). Cellular senescence as a tumor-suppressor mechanism. Trends in Cell Biology, 11:S27-S31.
46. Gosselin K and Abbadie C (2003). Involvement of Rel/NF-kappa B transcription factors in senescence. Exp Gerontol, 38:1271-83.
47. McCay CM, Crowell, M.F., and Maynard, L.A. (1935). The effect of retarded grwoth upon the length of life span and upon the ultimate body size. Nutritions, 5:155-71.
48. Anderson RM, Shanmuganayagam D, and Weindruch R (2009). Caloric restriction and aging: studies in mice and monkeys. Toxicol Pathol, 37:47-51.
49. Colman RJ, Beasley TM, Allison DB, and Weindruch R (2008). Attenuation of sarcopenia by dietary restriction in rhesus monkeys. J Gerontol A Biol Sci Med Sci, 63:556-9.
50. Kim HJ, Jung KJ, Yu BP, Cho CG, Choi JS, and Chung HY (2002). Modulation of redox-sensitive transcription factors by calorie restriction during aging. Mech Ageing Dev, 123:1589-95.
51. Higami Y, Barger JL, Page GP, Allison DB, Smith SR, Prolla TA, and Weindruch R (2006). Energy restriction lowers the expression of genes linked to inflammation, the cytoskeleton, the extracellular matrix, and angiogenesis in mouse adipose tissue. J Nutr, 136:343-52.
52. Jung KJ, Lee EK, Kim JY, Zou Y, Sung B, Heo HS, Kim MK, Lee J, Kim ND, Yu BP, and Chung HY (2009). Effect of short term calorie restriction on pro-inflammatory NF-kB and AP-1 in aged rat kidney. Inflamm Res, 58:143-50.
53. Kenyon CJ (2010). The genetics of ageing. Nature, 464:504-12.
54. Salminen A, Ojala J, Huuskonen J, Kauppinen A, Suuronen T, and Kaarniranta K (2008). Interaction of aging-associated signaling cascades: inhibition of NF-kappaB signaling by longevity factors FoxOs and SIRT1. Cell Mol Life Sci, 65:1049-58.
55. Salminen A and Kaarniranta K (2010). Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kappaB signaling. Cell Signal, 22:573-7.
56. Al-Regaiey KA, Masternak MM, Bonkowski M, Sun L, and Bartke A (2005). Long-lived growth hormone receptor knockout mice: interaction of reduced insulin-like growth factor i/insulin signaling and caloric restriction. Endocrinology, 146:851-60.
57. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS, Jr., and Mayo MW (2000). Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol, 20:1626-38.
58. Madrid LV, Mayo MW, Reuther JY, and Baldwin AS, Jr. (2001). Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem, 276:18934-40.
59. Bertrand F, Desbois-Mouthon C, Cadoret A, Prunier C, Robin H, Capeau J, AtfiA, and Cherqui G (1999). Insulin antiapoptotic signaling involves insulin activation of the nuclear factor kappaB-dependent survival genes encoding tumor necrosis factor receptor-associated factor 2 and manganese-superoxide dismutase. J Biol Chem, 274:30596-602.
60. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, and Anderson KC (2002). Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene, 21:5673-83.
61. Balaram SK, Agrawal DK, and Edwards JD (1999). Insulin like growth factor-1 activates nuclear factor-kappaB and increases transcription of the intercellular adhesion molecule-1 gene in endothelial cells. Cardiovasc Surg, 7:91-7.
62. Che W, Lerner-Marmarosh N, Huang Q, Osawa M, Ohta S, Yoshizumi M, Glassman M, Lee JD, Yan C, Berk BC, and Abe J (2002). Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression. Circ Res, 90:1222-30.
63. Niedernhofer LJ and Robbins PD (2008). Signaling mechanisms involved in the response to genotoxic stress and regulating lifespan. Int J Biochem Cell Biol, 40:176-80.
64. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, and de Cabo R (2008). Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab, 8:157-68.
65. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, and Tsai LH (2007). SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. Embo J, 26:3169-79.
66. Liu ZP, Li WX, Yu B, Huang J, Sun J, Huo JS, and Liu CX (2005). Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. J Med Food, 8:14-9.
67. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, and Sinclair DA (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444:337-42.
68. Lavu S, Boss O, Elliott PJ, and Lambert PD (2008). Sirtuins--novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov, 7:841-53.
69. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, and Mayo MW (2004). Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J, 23:2369-80.
70. Ghosh HS, Spencer JV, Ng B, McBurney MW, and Robbins PD (2007). Sirt1 interacts with transducin-like enhancer of split-1 to inhibit nuclear factor kappaB-mediated transcription. Biochem J, 408:105-11.
71. Sinclair D, Mills K, and Guarente L (1998). Aging in Saccharomyces cerevisiae. Annu Rev Microbiol, 52:533-60.
72. Guarente L (2000). Sir2 links chromatin silencing, metabolism, and aging. Genes Dev, 14:1021-6.
73. Peng SL (2007). Immune regulation by Foxo transcription factors. Autoimmunity, 40:462-9.
74. Lin L, Hron JD, and Peng SL (2004). Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity, 21:203-13.
75. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, and Sonenberg N (2006). mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer, 94:195-9.
76. Jia K, Chen D, and Riddle DL (2004). The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development, 131:3897-906.
77. Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, and Muller F (2003). Genetics: influence of TOR kinase on lifespan in C. elegans. Nature, 426:620.
78. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, and Benzer S (2004). Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol, 14:885-90.
79. Syntichaki P, Troulinaki K, and Tavernarakis N (2007). eIF4E function in somatic cells modulates ageing in Caenorhabditis elegans. Nature, 445:922-6.
80. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, and Baldwin AS (2008). Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev, 22:1490-500.
81. Salminen A and Kaarniranta K (2009). NF-kappaB signaling in the aging process. J Clin Immunol, 29:397-405.
82. Dan HC and Baldwin AS (2008). Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol, 180:7582-9.
83. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, and Hung MC (2007). IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell, 130:440-55.
84. Schumacher B, van der Pluijm, I, Moorhouse. M.J., Rasile Robinson, A., Suh, Y., Breit, T.M., van Steeg, H., Niedernhofer, L.J., van Ijcken, W., Bartke, A., Spindler, S.R., Hoeijmakers, J.H.J., van der Horst, G.J. and George A. Garinis (2008). Parallels in genome-wide expression changes between long-lived and progeroid mice reveal a survival response promoting longevity. PLoS Genet:(In Press).
85. Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, Odijk H, Oostendorp R, Ahmad A, van Leeuwen W, Theil AF, Vermeulen W, van der Horst GT, Meinecke P, Kleijer WJ, Vijg J, Jaspers NG, and Hoeijmakers JH (2006). A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature, 444:1038-43.
86. Veuger SJ and Durkacz BW (2011). Persistence of unrepaired DNA double strand breaks caused by inhibition of ATM does not lead to radio-sensitisation in the absence of NF-kappaB activation. DNA repair, 10:235-44.
87. Cuaz-Perolin C, Billiet L, Bauge E, Copin C, Scott-Algara D, Genze F, Buchele B, Syrovets T, Simmet T, and Rouis M (2008). Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice. Arterioscler Thromb Vasc Biol, 28:272-7.
88. Berenbaum F (2004). Signaling transduction: target in osteoarthritis. Curr Opin Rheumatol, 16:616-22.
89. Yamamoto Y and Gaynor RB (2001). Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med, 1:287-96.
90. Kim HJ, Chang EJ, Kim HM, Lee SB, Kim HD, Su Kim G, and Kim HH (2006). Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha. Free Radic Biol Med, 40:1483-93.
91. Valen G (2004). Signal transduction through nuclear factor kappa B in ischemia-reperfusion and heart failure. Basic Res Cardiol, 99:1-7.
92. Steinman L (2008). Nuanced roles of cytokines in three major human brain disorders. J Clin Invest, 118:3557-63.
93. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, 3rd, and Araoz C (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A, 86:7611-5.
94. Rahman SM, Van Dam AM, Schultzberg M, and Crisby M (2005). High cholesterol diet results in increased expression of interleukin-6 and caspase-1 in the brain of apolipoprotein E knockout and wild type mice. J Neuroimmunol, 169:59-67.
95. Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, and Griffin WS (1996). In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging, 17:761-6.
96. Combs CK, Karlo JC, Kao SC, and Landreth GE (2001). beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci, 21:1179-88.
97. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, and Gan L (2005). SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem, 280:40364-74.
98. Grilli M, GoffiF, Memo M, and Spano P (1996). Interleukin-1beta and glutamate activate the NF-kappaB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. J Biol Chem, 271:15002-7.
99. Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, Warner DS, and Laskowitz DT (2003). APOE Genotype and an ApoE-mimetic Peptide Modify the Systemic and Central Nervous System Inflammatory Response. J Biol Chem, 278:48529-48533.
100. Wyss-Coray T (2006). Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med, 12:1005-15.
101. Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, and Perry VH (2003). Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry, 74:788-9.
102. Miller RL, James-Kracke M, Sun GY, and Sun AY (2009). Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res, 34:55-65.
103. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, and Nagatsu T (1994). Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett, 165:208-10.
104. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, and Nagatsu T (1996). Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett, 211:13-6.
105. Delgado M and Ganea D (2003). Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J, 17:944-6.
106. McGeer PL, Itagaki S, Boyes BE, and McGeer EG (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38:1285-91.
107. Scheller C, Sopper S, Jenuwein M, Neuen-Jacob E, Tatschner T, Grunblatt E, ter Meulen V, Riederer P, and Koutsilieri E (2005). Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. J Neurochem, 95:377-87.
108. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong J-S, and Zhang J (2005). Aggregated a-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. The FASEB Journal, 19:533-542.
109. Croisier E, Moran LB, Dexter DT, Pearce RK, and Graeber MB (2005). Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation, 2:14.
110. Gao HM, Liu B, Zhang W, and Hong JS (2003). Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J, 17:1954-6.
111. Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza YPM, Fernandez-Barreiro A, Hirsch EC, and Herrero MT (2004). Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia, 46:402-9.
112. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, and Di Monte DA (2002). Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat. Neurobiol Dis, 10:119-127.
113. Miller RL, Sun GY, and Sun AY (2007). Cytotoxicity of paraquat in microglial cells: Involvement of PKCd- and ERK1/2-dependent NADPH oxidase. Brain Res, 1167:129-139.
114. Gao HM, Hong JS, Zhang W, and Liu B (2002). Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci, 22:782-90.
115. Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, Garcia de Yebenes J, and Mena MA (2006). Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem, 97:934-46.
116. Li G, Cui G, Tzeng N-S, Wei S-J, Wang T, Block ML, and Hong J-S (2005). Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. The FASEB Journal, 19:489-496.
117. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, and Hirsch EC (1997). Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A, 94:7531-6.
118. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, and Pahan K (2007). Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A, 104:18754-9.
119. Panet H, Barzilai A, Daily D, Melamed E, and Offen D (2001). Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J Neurochem, 77:391-8.
120. Perry VH, Cunningham C, and Holmes C (2007). Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol, 7:161-7.
121. Gao HM, Liu B, Zhang W, and Hong JS (2003). Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci, 24:395-401.
122. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, and Kalofoutis A (2006). Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci, 1084:89-117.
123. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, and Shoelson SE (2001). Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science, 293:1673-7.
124. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, and Shoelson SE (2005). Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med, 11:183-90.
125. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, and Chen H (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest, 112:1821-30.
126. Tanegashima K, Okamoto S, Nakayama Y, Taya C, Shitara H, Ishii R, Yonekawa H, Minokoshi Y, and Hara T (2010). CXCL14 deficiency in mice attenuates obesity and inhibits feeding behavior in a novel environment. PLoS One, 5:e10321.
127. Giannoukakis N, Rudert WA, Ghivizzani SC, Gambotto A, Ricordi C, Trucco M, and Robbins PD (1999). Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro. Diabetes, 48:1730-6.
128. Uysal KT, Wiesbrock SM, Marino MW, and Hotamisligil GS (1997). Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature, 389:610-4.
129. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, and Kalofoutis A (2006). Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci, 1084:89-117.
130. Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, and Feldmann M (2004). Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci U S A, 101:5634-9.
131. Kleemann R, Zadelaar S, and Kooistra T (2008). Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res, 79:360-76.
132. Csiszar A, Labinskyy N, Smith K, Rivera A, Orosz Z, and Ungvari Z (2007). Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging. Am J Pathol, 170:388-98.
133. TzankoffSP and Norris AH (1977). Effect of muscle mass decrease on age-related BMR changes. J Appl Physiol, 43:1001-6.
134. Bautmans I, Njemini R, Lambert M, Demanet C, and Mets T (2005). Circulating acute phase mediators and skeletal muscle performance in hospitalized geriatric patients. J Gerontol A Biol Sci Med Sci, 60:361-7.
135. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M, and Harris TB (2002). Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci, 57:M326-32.
136. Cai D, Frantz JD, Tawa NE, Jr., Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, and Shoelson SE (2004). IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell, 119:285-98.
137. Hunter RB, Stevenson E, Koncarevic A, Mitchell-Felton H, Essig DA, and Kandarian SC (2002). Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. FASEB J, 16:529-38.
138. Kandarian SC and Jackman RW (2006). Intracellular signaling during skeletal muscle atrophy. Muscle Nerve, 33:155-65.
139. Hunter RB and Kandarian SC (2004). Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. The Journal of Clinical Investigation, 114:1504-1511.
140. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, Li ZW, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner KL, Rafael-Fortney JA, Karin M, Tidball JG, Baldwin AS, and Guttridge DC (2007). Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest, 117:889-901.
141. Yun AJ and Lee PY (2004). Maldaptation of the link between inflammation and bone turnover may be a key determinant of osteoporosis. Med Hypotheses, 63:532-7.
142. Soysa NS and Alles N (2009). NF-kappaB functions in osteoclasts. Biochem Biophys Res Commun, 378:1-5.
143. Ding C, Parameswaran V, Udayan R, Burgess J, and Jones G (2008). Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab, 93:1952-8.
144. Ginaldi L, Di Benedetto MC, and De Martinis M (2005). Osteoporosis, inflammation and ageing. Immun Ageing, 2:14.
145. Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach PH, and Wang CY (2009). Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med, 15:682-9.
146. Terzic J, Marinovic-Terzic I, Ikeda F, and Dikic I (2007). Ubiquitin signals in the NF-kappaB pathway. Biochem Soc Trans, 35:942-5.
147. www.proteinlounge.com, NF-kB Signaling, in jpeg. 2005.